Biomarkers as prognostic factors in endometrial cancer

Folia Histochemica et Cytobiologica

Volumn 48, Issue 3, 2010, Pages 319-322

  Dobrzycka, Bozena ^a   Terlikowski, Sławomir J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Biomarker; Endometrial cancer; Prognosis

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; STEROID RECEPTOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER STEM CELL; DNA DAMAGE; DNA SEQUENCE; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE MUTATION; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NULLIPARA; ONCOGENE; PLOIDY; PROGNOSIS; RISK FACTOR; TUMOR SUPPRESSOR GENE;

EID: 78649574442     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-10-0061-8     Document Type: Article

References (45)

1. Horner MJ, Ries LAG, Krapcho M. et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
2. Stewart BW, Kleihues P. World cancer report. Lyon: IARC Press, 2003.
3. Reports based on data of National Cancer Registry. The Maria Sklodowska-Curie memorial Cancer Center, Department of Epidemiology and Cancer Prevetion, National Cancer Registry 2004, http://epid.coi.waw.pl/krn.
4. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS. 2009; 117(10):693-707.
5. Garg K, Shih K, Barakat R. et al. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol. 2009; 33(12):1869-1877.
6. Garg K, Soslow RA. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol. 2009; 62(8):679-684.
7. Fader AN, Arriba LN, Frasure HE. et al. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009; 114(1):121-127.
8. Dobrzycka B, Terlikowski SJ, Mazurek A. et al. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer. 2010; 127(3):612-621.
9. Dobrzycka B, Terlikowski SJ, Mazurek A. et al. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. Folia Histochem Cytobiol. 2009; 47(1):65-68.
10. Terlikowski S, Lenczewski A, Famulski W. et al. Patterns of immunohistochemical staining for p53 expression in hyperplastic endometrium and adenocarcinoma. Folia Histochem Cytobiol. 2001; 39 Suppl 2:195-196.
11. Terlikowski S, Lenczewski A, Famulski W. et al. Proliferative activity in endometrial hyperplasia and adenocarcinoma. Folia Histochem Cytobiol. 2001; 39(2):163-164.
12. Amant F, Moerman P, Neven P. et al. Endometrial cancer. Lancet. 2005; 366(9484):491-505.
13. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol. 2007; 46(1):26-32.
14. Jongen VH, Briët JM, de Jong RA. et al. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer. 2009; 19(4):670-676.
15. Konecny GE, Santos L, Winterhoff B. et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009; 100(1):89-95.
16. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int. 2010; 2010: 162363. Epub 2010 Mar 28.
17. Dobrzycka B, Terlikowski SJ, Kowalczuk O. et al. Mutations in the KRAS gene in ovarian tumors. Folia Histochem Cytobiol. 2009; 47(2):221-224.
18. Oda K, Stokoe D, Taketani Y. et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005; 65(23):10669-10673.
19. Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol. 2009; 5(1):27-32.
20. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009; 16(1):8-13.
21. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789-799.
22. Llobet D, Pallares J, Yeramian A. et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol. 2009; 62(9):777-785.
23. Salvesen HB, Kumar R, Stefansson I. et al. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer. 2005; 115(6):930-934.
24. Sulewska A, Niklinska W, Kozlowski M. et al. DNA methylation in states of cell physiology and pathology. Folia Histochem Cytobiol. 2007; 45(3):149-158.
25. Prat J, Gallardo A, Cuatrecasas M. et al. Endometrial carcinoma: pathology and genetics. Pathology. 2007; 39(1):72-87.
26. Mangili G, Montoli S, De Marzi P. et al. The role of DNA ploidy in postoperative management of stage I endometrial cancer. Ann Oncol. 2008; 19(7):1278-1283.
27. Susini T, Amunni G, Molino C. et al. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called low-risk patients with well and moderately differentiated tumors. Cancer. 2007; 109(5):882-890.
28. Ito K, Utsunomiya H, Yaegashi N. et al. Biological roles of estrogen and progesterone in human endometrial carcinomanew developments in potential endocrine therapy for endometrial cancer. Endocr J. 2007; 54(5):667-679.
29. Kleine WW. Prognostic value of progesterone receptors in endometrial cancer. Cancer Treat Res. 1994; 70: 93-100.
30. Sivridis E, Giatromanolaki A, Koukourakis M. et al. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch. 2001; 438(5):470-477.
31. Sivridis E. Angiogenesis and endometrial cancer. Anticancer Res. 2001; 21(6B):4383-4388.
32. Krikun G, Schatz F, Lockwood CJ. Endometrial angiogenesis: from physiology to pathology. Ann N Y Acad Sci. 2004; 1034:27-35.
33. Dobrzycka B, Terlikowski SJ, Kwiatkowski M et al. Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer. Ginekol Pol. 2010; 81:422-425.
34. Donoghue JF, Lederman FL, Susil BJ. et al. Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma. Hum Reprod. 2007; 22(6):1705-1713.
35. Mannelqvist M, Stefansson I, Salvesen HB. et al. Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology. 2009; 54(2):174-183.
36. Abal M, Llauradó M, Doll A. et al. Molecular determinants of invasion in endometrial cancer. Clin Transl Oncol. 2007; 9(5): 272-277.
37. Dobrzycka B, Terlikowski SJ, Garbowicz M. et al. Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer. Folia Histochem Cytobiol. 2009;47(4):609-613.
38. Hazan RB, Qiao R, Keren R. et al. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004; 1014:155-163.
39. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol. 2004; 22(7): 1242-1252.
40. Fukuchi T, Sakamoto M, Tsuda H. et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 1998; 58(16):3526-3528.
41. Leoeniewicz T, Kanczuga-Koda L, Baltaziak M. et al. Expression of connexin 26 in endometrial adenocarcinoma-analysis of correlations with some anatomoclinical features. Folia Histochem Cytobiol. 2008; 46(2):171-176.
42. Miller SJ, Lavker RM, Sun TT. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta. 2005; 1756(1):25-52.
43. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med. 2006;12(3):296-300.
44. Gargett CE. Uterine stem cells: what is the evidence? Hum Reprod Update. 2007; 13(1):87-101.
45. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-17.